Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07507838

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules

This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics （PK） of multiple doses of VV913 in Chinese healthy adult participants.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy Volunteers

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Early Phase 1

Primary location

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230031, China

Location status: Recruiting

Location contact

Huan Zhou

CONTACT

[email protected]

13665527160

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 45 years old, males ;
  • Males weight no less than 50 kg, with body mass index of 19 to 26 kg/m^2;
  • Vital signs examination, physical examination, laboratory examination ,Chest X-ray are normal or considered abnormal without clinical significance by the investigator;
  • Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;
  • Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form.

Exclusion criteria

  • Participants with hypersensitivity to preparation or any of the excipients;
  • Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
  • Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; Participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);
  • Participants with a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;
  • Participants with a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a history of blood product use within 3 months before screening;
  • Participating in any clinical trial and taking clinical trial drugs within 90 days before screening;
  • Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before screening;
  • Participants who have received vaccination within 14 days before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;
  • Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
  • Participants who drink more than 14 standard units or at least twice a day per week within one year before screening (one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content);
  • Participants who smoke more than 5 cigarettes a day within one year before screening;
  • Participants who can't quit smoking or drinking during the trial period;
  • Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV）;
  • Having special requirements for food, unable to observe a unified diet or having dysphagia;
  • Participants who cannot avoid consuming drinks containing xanthine (such as coffee and tea) or foods (such as chocolate and animal liver), or fruits or juices (such as grapefruit, pomelo, mango, and dragon fruit) that may affect drug metabolism，from 48 hours before administration until the end of the study;
  • Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
  • Participants with difficulty in swallowing capsules;
  • Participants whose female partners plan to conceive within 3 months;
  • The investigator believes that there are other unsuitable factors to participate this trial.

Treatment and study plan

VV913 4mg group

Drug

6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

VV913 8mg group

Drug

6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

VV913 15mg group

Drug

6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: Baseline to 6 days after the last administration

    Incidence of Treatment-Emergent Adverse Events

  2. Cmax

    Time frame: Baseline to 72 hours after the last administration

    maximum observed plasma concentration

  3. AUC0-∞

    Time frame: Baseline to 72 hours after the last administration

    area under the plasma concentration time curve from time zero to infinity

  4. Tmax

    Time frame: Baseline to 72 hours after the last administration

    time at which Cmax occurs

  5. t1/2

    Time frame: Baseline to 72 hours after the last administration

    half-life of elimination

  6. Apparent Clearance Rate（CL/F）

    Time frame: Baseline to 72 hours after the last administration

    apparent clearance

  7. Vd/F

    Time frame: Baseline to 72 hours after the last administration

    apparent volume of distribution during the terminal phase

  8. λz

    Time frame: Baseline to 72 hours after the last administration

    elimination rate constant

  9. AUC0-24h

    Time frame: Baseline to 72 hours after the last administration

    area under the plasma concentration time curve from time zero to 24h

  10. mean Resident Time

    Time frame: Baseline to 72 hours after the last administration

    mean Resident Time from time zero to infinity/the last

  11. Rac

    Time frame: Baseline to 72 hours after the last administration

    Accumulation Ratio of VV913

Study contacts

Contact information is provided by the study sponsor or research team.

Huaqing Duan

CONTACT

[email protected]

18061926005

Sponsors and collaborators

Lead sponsor

Vigonvita Life Sciences

Industry

Registry information

Official study title

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules in Chinese Healthy Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 2, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.